Antoniotti C, Marmorino F, Rossini D, Schmoll HJ, et al. FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials. Eur J Cancer 2025;228:115713.
PMID: 40865392